Cardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in Epigenomics
- Affordable, scalable framework using AI-guided epigenetic assessments for CHD risk assessment, diagnosis, and management
- Potentially disruptive blood-based DNA test, PrecisionCHD™, can be performed within hours using standard laboratory equipment
- Current diagnostic methods have significant limitations with respect to sensitivity, scalability, and assessment-related morbidity
This review lays out an affordable, scalable framework to use artificial intelligence-guided epigenetic assessments for CHD risk assessment, diagnosis, and management. The digital PCR-based approach requires only minimal infrastructure investments while providing unparalleled personalized biological insights into the drivers of each patient's CHD presentation.
According to the manuscript published online on September 13th, current diagnostic methods like angiograms and exercise ECGs have significant limitations with respect to sensitivity, scalability, and assessment-related morbidity. These difficulties increase the real-world cost of these tests and hinder the use of these tests in developing economies or rural areas.
In response to these challenges, the Broyles’ led review describes a potentially disruptive blood-based DNA test, PrecisionCHD™. This test uses easily performed digital PCR laboratory assays to quantify epigenetic signatures that are interpreted by artificial intelligence (AI) to determine the presence or absence of CHD. Though it required years of development, the PrecisionCHD™ test can now be performed within hours using standard laboratory equipment.
"Without a doubt, the future in precision epigenetics for diagnosing and managing CHD is bright. We stand on the cusp of a transformative era, with the potential to bring high-quality CHD care to all corners of the globe,” noted lead author Damon Broyles, MD, the VP of Clinical Innovation, Medical Director of Precision Medicine and Vice Chair of Mercy Board of Research.
"Our research shows a clear pathway for precision epigenetics to fill critical unmet needs in cardiac care on a national and global scale," said Dr. Robert Philibert, Chief Medical Officer and Co-Founder of Cardio Diagnostics. "Combining next-generation epigenomics and AI enables earlier CHD detection, improved risk stratification, and optimized treatment selection for patients without risk from radiation or contrast dye-induced kidney damage,” shared Dr. Philibert. “Furthermore, because the signatures are dynamic, periodic retesting of key sites may allow clinicians to determine the effectiveness of therapy and help usher in a new era of Precision Epigenetics approaches for managing cardiovascular care,” he added.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.
Forward-Looking Statements
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended June 30, 2023 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230920184442/en/
Investors:
Gene Mannheimer
Investor Relations
855-226-9991
investors@cardiodiagnosticsinc.com
Media & Public Relations:
Khullani Abdullahi
pr@cardiodiagnosticsinc.com
Source: Cardio Diagnostics Holdings, Inc
